Oncology Based In-Vivo CRO Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922032|
|出版日期||內容資訊||英文 113 Pages
|全球CRO的In Vivo腫瘤市場:成長，趨勢，及預測 Oncology Based In-Vivo CRO Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 113 Pages||
The Oncology Based In-Vivo CRO market studied is anticipated to grow with a CAGR of 7.3%, during the forecast period. The major factors attributing to the growth of the oncology based In-Vivo CRO market are the rising incidence of cancer cases worldwide. A rise in the geriatric population is also propelling the growth for the oncology based In-Vivo CRO market. Owing to the increasing number of specific therapies in the oncology pipeline and the presence of large number of pipeline drugs, the number of late-stage pipeline therapies rose from 711 in 2017 to 849 in 2018 - an increase of 19% and the use of oncology based In-Vivo CRO help in deriving the novel therapies for the diagnosis, prevention, and treatment to patients which is further expected to boost the market growth. In addition to the development of vaccines for infectious diseases, oncology is among the most studied indication, as per the statistics available from government agencies around the world. And there are few more factors that are playing crucial roles in taking the oncology based In-Vivo CRO market to the next level, among them federal funding for research studies and increasing treatment for cancer and research expertise, which are expected to propel the growth of oncology based In-Vivo CRO market. As per the North American Association of Central Cancer Registries (NAACCR) 2019 data, there will be an estimated 176,2450 new cancer cases in the U.S.
The oncology based In-Vivo CRO provides preclinical drug development, testing and infection diagnosis research in the field of oncology. The demand for research organizations in In-Vivo Contract is growing as pharmaceutical companies are increasing their pipeline drugs to create and produce new molecules to retain strong benefits and patent products in the marketplace.
Solid Tumor Segment is Expected to Hold the Largest Market Share in the Oncology Based In-Vivo CRO Market
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall oncology based In-Vivo CRO market, throughout the forecast period. This is owing to factors such as the rising prevalence of cancer and the availability of advanced healthcare infrastructure and the presence of a large number of CROs in the region among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer, along with the rising geriatric population and research & developments related to cancer therapy and rising government initiative for the awareness of cancer in the country, is anticipated to further drive the oncology based In-Vivo CRO market in this region.
The oncology based In-Vivo CRO market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Crown Bioscience Inc., Charles River Laboratories, Inc., ICON plc, Taconic Biosciences, Inc., and Covance Inc.